Torbay Pharma strengthens leadership team to support North American growth strategy

PAIGNTON, UK, 7 May 2024 – Torbay Pharma, a global specialist in the manufacture and supply of terminally sterilized injectables for the secondary care market, has boosted its North American growth strategy by bringing on board industry-leading professionals to strengthen its senior leadership team.

 

Accelerated by its recent investment from private equity firm, NorthEdge, the contract manufacturer (CMO) and license holder has hired Mohammed Nazir (Naz) as COO and Tara Slivey, CPO, who both have extensive pharma experience in executive roles.

 

Naz has worked for Pantheon and Pfizer and will be using his operational expertise to support our manufacturing growth plans. Tara has substantial experience in working in people and cultural development teams and also has experience of working in pharmaceutical manufacturing for businesses owned by private equity.

 

Emma Rooth, CEO of Torbay Pharma, said: “As we expand in North America we’re staying focused on innovation, efficiency, and, most importantly, patient wellbeing. As well as bolstering our leadership team to supercharge our growth, we’re currently working with the FDA to support our bid to gain approval.

 

“The expansion couldn’t come at a more crucial time as the healthcare sector in the US grapples with supply chain challenges and increasing demand for essential medicines. Many of the products we manufacture are already top of the shortage list in the US, highlighting the indispensable role Torbay Pharma can play.”

 

The CMO has already reached a major milestone in its investment plans by completing the first phase of its packaging automation programme, which will significantly speed up the process from manufacturing to release.

 

Emma added: “Torbay Pharma is continually looking at opportunities to invest in and expand our services. Over the next few years, we will be increasing automation in our packaging and warehousing department. We also have an ongoing programme to look at how we use technology to increase automation, generate efficiencies and improve flexibility as we continue to grow.”

 

Renowned for its specialist expertise in the filling of generic injectables into both plastic and glass containers, Torbay Pharma has already seen a rise in demand for its plastic parenteral nutrition (PN) products across the North American landscape over the past two years.

 

 

For more information about Torbay Pharma and its expansion plans, please visit our website www.torbaypharma.com

 

 

 

ENDS

 

 

Torbay Pharmaceuticals (Torbay) is a sterile injectable contract manufacturer and licence holder based in Paignton, UK. Established in the 1970s as part of the Torbay and Devon NHS Foundation Trust, Torbay has grown to a 250-strong team serving an international client base of healthcare organisations and pharmaceutical companies. It received investment from private equity firm NorthEdge in November 2023 and became Torbay Pharmaceuticals Ltd.

 

As a CMO, Torbay offers fill/finish services for terminally sterilised injectables into plastic and glass vials. It specialises in small to medium-sized commercial batches of generic small-molecule drug products. The company’s specialist portfolio includes licensed and unlicensed terminally sterilised injectables, electrolyte solutions for total parenteral nutrition (TPN) compounding and a range of non-sterile oral solutions.  

 

For more information on Torbay Pharmaceuticals, visit: www.torbaypharma.com 

 

 

PR Manager

ramarketing

aranda@ramarketingpr.com

+44(0)191 222 1242